GlassScriptPhysician profile
Gerald Y Ho
NPI 1205833662
$6,366.24
in general payments reported to CMS, 2019-2025
37 companies · $85.68 in 2025
The $85.68 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,137 · 2020: $46.17 · 2021: $249 · 2022: $297 · 2023: $846 · 2024: $1,706 · 2025: $85.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349 · Travel and Lodging: $261 · Education: $28.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,348.67 |
| Travel and Lodging | $260.63 |
| Education | $28.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,535.65 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $821.47 | 2019-2024 | |
| Horizon Therapeutics Plc | $702.20 | 2019-2023 | Krystexxa |
| Pfizer INC. | $516.86 | 2019-2024 | |
| Ucb Sa | $401.61 | 2024 | |
| Abbvie INC. | $372.99 | 2019-2025 | |
| Celgene Corporation | $239.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $201.11 | 2019-2024 | Orencia |
| Janssen Biotech, INC. | $181.16 | 2019 | |
| Mallinckrodt Enterprises LLC | $171.76 | 2019 | |
| Alexion Pharmaceuticals, INC. | $141.09 | 2023-2024 | Strensiq |
| Depuy Synthes Sales INC. | $102.32 | 2019-2024 | Orthovisc |
| Lilly USA, LLC | $98.34 | 2019-2024 | Zepbound, Taltz |
| Radius Health, INC. | $92.03 | 2019 | |
| Glaxosmithkline, LLC. | $87.90 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $77.13 | 2024 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $74.53 | 2019 | |
| Ucb, INC. | $68.44 | 2019 | |
| Genentech USA, INC. | $68.29 | 2019 | |
| Zimmer Biomet Holdings, INC. | $48.43 | 2019-2024 | Gel-One Cross-Linked Hyaluronate |
| Medexus Pharma, INC. | $45.86 | 2019 | |
| Fidia Pharma USA INC. | $44.13 | 2019 | |
| Gilead Sciences, INC. | $42.89 | 2022-2024 | |
| Genzyme Corporation | $39.84 | 2019 | |
| Ferring Pharmaceuticals INC. | $35.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.76 | 2023-2024 | Saphnelo |
| Boston Scientific Corporation | $29.72 | 2023 | Bodyguardian |
| Abbott Laboratories | $25.45 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $19.37 | 2019 | |
| Sobi, INC | $14.84 | 2019 | |
| Hikma Pharmaceuticals USA | $13.28 | 2019 | |
| Forte Bio-Pharma LLC | $13.12 | 2019 | |
| Organon LLC | $6.92 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.